Clinical Trial

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)

Name: Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA) — clinical trial record (NCT07629596)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated Autoimmune Disease

Trial Details

NCT Number	NCT07629596
Lead Sponsor	Circunited BioPharma (Shenzhen) Co., Ltd. Collaborators: Boji Medical Technology Co., Ltd.
Conditions	Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA)
Enrollment	5 participants
Start Date	2026-04-07
Primary Completion	2027-05-30 (estimated)
Study Completion	2027-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-05